Lys006 | 1799681-85-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Lys006
• 英文别名: (3S)-3-amino-4-[5-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenyl]tetrazol-2-yl]butanoic acid
• CAS: 1799681-85-8
• 化学式: C₁₆H₁₄ClFN₆O₃
• 分子量: 392.77
• InChiKey: ZEGMEJVULDALSH-NSHDSACASA-N

物化性质

• 沸点：
  583.1±60.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：250 mg/mL（636.50 mM；需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF<br/>[FR] DÉRIVÉS DE SPIROPIPÉRIDINYLE SUBSTITUÉS PAR HÉTÉROARYLE ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：NOVARTIS AG

  公开号：WO2022034529A1

  公开（公告）日：2022-02-17

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物(I)或其药用可接受盐；(I)中R1、R2、R4和X1的定义见本文，本发明化合物的制备方法以及其治疗用途。本发明还提供了药理活性剂的组合和药物组合物。
• [EN] HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE HÉTÉROARYL BUTANOÏQUE EN TANT QU'INHIBITEURS DE LA LTA4H
  申请人：NOVARTIS AG

  公开号：WO2015092740A1

  公开（公告）日：2015-06-25

  The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.

  本发明描述了新颖的杂环烷基丁酸衍生物，特别是在白三烯A4水解酶（LTA4H）方面具有良好的药物候选性。本发明还涉及包含所述新颖的杂环烷基丁酸衍生物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些新颖化合物的方法。
• [EN] CRYSTALLINE FORMS OF A LTA4H INHIBITOR<br/>[FR] FORMES CRISTALLINES D'UN INHIBITEUR DE LTA4H
  申请人：NOVARTIS AG

  公开号：WO2020026108A1

  公开（公告）日：2020-02-06

  This application relates to various crystalline forms of (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ("hydrates"). These materials are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of LTA4H. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation.

  本申请涉及自由形式下的(S)-3-氨基-4-(5-(4-((5-氯-3-氟吡啶-2-基)氧基)苯基)-2H-四唑-2-基)丁酸的各种晶体形式，以及其组合物、制备方法和使用方法。在某些实施例中，晶体形式还包含水分子（“水合物”）。这些材料可用于治疗通常通过抑制LTA4H改善的疾病和疾病，例如炎症和自身免疫性疾病以及肺部和呼吸道炎症。
• [EN] METHODS OF TREATING LIVER DISEASE USING LTA4H INHIBITORS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UNE MALADIE HÉPATIQUE À L'AIDE D'INHIBITEURS DE LTA4H
  申请人：NOVARTIS AG

  公开号：WO2021044351A1

  公开（公告）日：2021-03-11

  The present disclosure relates to methods for treating or preventing a liver disease, using a LTA4H inhibitor, alone or in combination with another therapeutic agent, e.g. a FXR agonist. Also disclosed herein are LTA4H inhibitors, for treating or preventing a liver disease or disorder, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

  本公开涉及使用LTA4H抑制剂单独或与另一种治疗药物（例如FXR激动剂）联合治疗或预防肝病的方法。本公开还涉及用于治疗或预防肝病或疾病的LTA4H抑制剂，以及用于上述用途和方法的药物、剂量方案、制药配方、组合、剂型和套装。
• [EN] LTA4H INHIBITORS FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA<br/>[FR] INHIBITEURS DE LTA4H POUR LE TRAITEMENT DE L'HIDROSADÉNITE SUPPURÉE
  申请人：NOVARTIS AG

  公开号：WO2020144604A1

  公开（公告）日：2020-07-16

  The present disclosure relates to methods for treating Hidradenitis Suppurativa using a LTA4H inhibitor. Also disclosed herein are LTA4H inhibitors, for treating Hidradenitis Suppurativa patients, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

  本公开涉及使用LTA4H抑制剂治疗汗腺炎脓肿的方法。本公开还披露了用于治疗汗腺炎脓肿患者的LTA4H抑制剂，以及用于所披露的用途和方法的药物、剂量方案、药物制剂、组合物、剂型和工具包。